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Hyperglycemiaandinsulinresistancearekeyplayersinthedevelopmentofatherosclerosisanditscomplications.Alargebodyofevidencesuggest
thatmetabolicabnormalitiescauseoverproductionofreactiveoxygenspecies(ROS).Inturn,ROS,viaendothelialdysfunctionandinﬂammation,
playamajorroleinprecipitatingdiabeticvasculardisease.AbetterunderstandingofROS-generatingpathwaysmayprovidethebasistodevelop
noveltherapeuticstrategiesagainstvascularcomplicationsinthissetting.PartIofthisreviewwillfocusonthemostcurrentadvancesinthepatho-
physiologicalmechanismsofvasculardisease:(i)emergingroleofendotheliuminobesity-inducedinsulinresistance;(ii)hyperglycemia-dependent
microRNAsderegulationandimpairmentofvascularrepaircapacities;(iii)alterationsofcoagulation,plateletreactivity,andmicroparticlerelease;
(iv)epigenetic-driventranscriptionofROS-generatingandproinﬂammatorygenes.Takentogetherthesenovelinsightspointtothedevelopment
of mechanism-based therapeutic strategies as a promising option to prevent cardiovascular complications in diabetes.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Thenumberofpeoplewithdiabetesmellitusisalarminglyincreasing
due to the growing prevalence of obesity, genetic susceptibility, ur-
banization, and ageing.
1,2
Type2diabetes,themostcommonformofthedisease,mayremain
undetectedformanyyearsanditsdiagnosisisoftenmadeincidentally
through an abnormal blood or urine glucose test. Hence, physicians
often face this disease at an advanced stage when vascular complica-
tionshavealreadyoccurredinmostofpatients.Macrovascularcompli-
cations are mainly represented by atherosclerotic disease and its
sequelae. Diabetes-related microvascular disease such as retinopathy
andnephropathyaremajorcausesofblindnessandrenalinsufﬁciency.
1
Based on this scenario, a better understanding ofthe mechanisms
underlying diabetic vascular disease is mandatory because it may
provide novel approaches to prevent or delay the development of
itscomplications.Thisreviewwillfocusonthemostcurrentadvances
in the pathophysiology of vascular disease (Part I) and will address
clinical manifestations and management strategies of patients with
diabetes (Part II).
Hyperglycemia, oxidative stress,
and vascular disease
The alterations in vascular homeostasis due to endothelial and
smooth muscle cell dysfunction are the main features of diabetic
vasculopathy favouring a pro-inﬂammatory/thrombotic state
which ultimately leads to atherothrombosis. Macro- and micro-
vasculardiabeticcomplicationsaremainlyduetoprolongedexpos-
ure to hyperglycemia clustering with other risk factors such as
arterialhypertension,dyslipidemiaaswellasgeneticsusceptibility.
3
Interestingly, nephropathy, retinopathy, and diabetic vascular
disease are in line with the notion that endothelial, mesangial, and
retinal cells are all equipped to handle high sugar levels when com-
pared with other cell types.
4 The detrimental effects of glucose
already occur with glycemic levels below the threshold for the
diagnosis of diabetes. This is explained by the concept of ‘glycemic
continuum’ across the spectrum of prediabetes, diabetes, and cardio-
vascular risk.
5–8 Early disglycemia caused by obesity-related insulin re-
sistance or impaired insulin secretion is responsible for functional and
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The initial trigger whereby high glucose concentrations alter vas-
cular function is the imbalance between nitric oxide (NO) bioavail-
ability and accumulation of reactive oxygen species (ROS), leading
to endothelial dysfunction.
9 Indeed, hyperglycemia-induced gener-
ationofsuperoxideanion(O2
2)inactivatesNOtoformperoxynitrite
(ONOO
2), a powerful oxidant which easily penetrates across
phospholipid membranes and induces substrate nitration.
9 Protein
nitrosylation blunts activity of antioxidant enzymes and endothelial
NOsynthase
10(eNOS,Figure1).Importantly,reducedNObioavail-
ability is a strong predictor of cardiovascular outcomes.
10,11
OverproductionofROSbymitochondriaisconsideredasacausal
link between elevated glucose and the major biochemical pathways
involvedinthedevelopmentofvascularcomplicationsofdiabetes.
12
Indeed,hyperglycemia-inducedROSproductiontriggersseveralcel-
lularmechanismsincludingpolyolandhexosamineﬂux,advancedgly-
cation end products (AGEs), protein kinase C (PKC) activation, and
NF-kB-mediatedvascularinﬂammation.
12,13Oneofthemainsources
ofROSinthesettingofhyperglycemiaisrepresentedbyPKCandits
downstream targets. The hyperglycemic environment induces a
chronicelevationofdiacyglycerollevelsinendothelialcellswithsub-
sequent membrane translocation of conventional (a, b1, b2) and
non-conventional(d) PKCisoforms.Onceactivated,PKCisrespon-
siblefordifferentstructuralandfunctionalchangesinthevasculature
includingalterationsincellularpermeability,inﬂammation,angiogen-
esis,cellgrowth,extracellularmatrixexpansion,andapoptosis.
14An
important consequence of PKC activationis ROS generation. In vas-
cular endothelial cells, hyperglycemia-induced activation of PKC
increases superoxide production via NADPH oxidase
15 (Figure 1).
Indeed, treatment with a PKCb inhibitor suppresses NADPH-
dependent ROS generation.
16
More recently, it has been reported that glucose-induced activa-
tion of PKC b2 isoform phosphorylates p66
Shc at serine 36 leading
to its translocation to the mitochondria, cytochrome c oxidation
and accumulation of ROS into the organelle.
17,18 The p66
Shc
adaptor protein functions as a redox enzyme implicated in mito-
chondrial ROS generation and translation of oxidative signals into
apoptosis.
17 Interestingly, diabetic p66
Shc2/2 mice are protected
againsthyperglycemia-inducedendothelialdysfunctionandoxidative
Figure 1 Mechanisms of hyperglycemia-induced vascular damage. High intracellular glucose concentrations lead to PKC activation and subse-
quent ROS production by NADPH oxidase and p66
Shc adaptor protein. Increased oxidative stress rapidly inactivates NO leading to formation
of the pro-oxidant ONOO
2 responsible for protein nitrosylation. Reduced NO availability is also due to PKC-dependent eNOS deregulation.
Indeed, PKC triggers enzyme up-regulation thus enhancing eNOS uncoupling and leading to a further accumulation of free radicals. On the
otherhand, hyperglycemiareduceseNOSactivity bluntingactivatory phosphorylationatSer1177.TogetherwiththelackofNO, glucose-induced
PKC activationcausesincreasedsynthesisofET-1favouringvasoconstrictionandplateletaggregation.Accumulationofsuperoxideanionalsotrig-
gers up-regulation of pro-inﬂammatory genes MCP-1, VCAM-1, and ICAM-1 via activation of NF-kB signalling. These events lead to monocyte ad-
hesion,rolling,anddiapedesiswithformationoffoamcellsinthesub-endotheliallayer.Foamcell-derivedinﬂammatorycytockinesmaintainvascular
inﬂammationaswellasproliferationofsmoothmusclecells,acceleratingtheatheroscleroticprocess.Endothelialdysfunctionindiabetesalsoderives
from increased synthesis of TXA2 via up-regulation of COX-2 and inactivation of PGIS by increased nitrosylation. Furthermore, ROS increase the
synthesisofglucosemetabolitemethylglyoxalleadingtoactivationofAGE/RAGEsignallingandthepro-oxidanthexosamineandpolyolpathwayﬂux.
PKC,proteinkinaseC;eNOS,endothelialnitricoxidesynthase;ET1,endothelin1;ROS,reactiveoxygenspecies;NO,nitricoxide;MCP-1, mono-
cytechemoattractantprotein-1;VCAM-1,vascularcelladhesionmolecule-1;ICAM-1,intracellularcelladhesionmolecule-1;AGE,advancedglyca-
tion end product.
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19 The relevance of p66
Shc in the clinical setting of diabetes is
supported by the notion that p66
Shc gene expression is increased
in peripheral blood mononuclear cells obtained from patients with
type 2 diabetes and correlates with plasma 8-isoprostane levels, an
in vivomarkerofoxidativestress.
20 Moreover,p66
Shcproteinhas re-
cently emerged as an upstream modulator of NADPH activation
further strengthening its pivotal role in ROS generation.
21,22
PKC affects NOavailability notonly via intracellularaccumulation
ofROSbutalsobydecreasingeNOSactivity.
23–25PKCalsoleadsto
increasedproductionofendothelin-1(ET-1)favouringvasoconstric-
tion and platelet aggregation
14 (Figure 1). The role of ET-1 in the
pathophysiologyofdiabeticcomplicationsisconﬁrmedbytheobser-
vation that the activity of endogenous ET-1 on ET(A) receptors is
enhanced in the resistance vessels of patients with diabetes.
26
In the vessel wall, PKC-dependent ROS production also partici-
patesin the atheroscleroticprocess bytriggering vascular inﬂamma-
tion.
13,27Indeed,ROSleadtoup-regulationandnucleartranslocation
of NF-kB subunit p65 and, hence, transcription of pro-inﬂammatory
genes encoding for monocyte chemoattractant protein-1 (MCP-1),
selectins, vascularcelladhesionmolecule-1(VCAM-1), andintracel-
lular cell adhesion molecule-1 (ICAM-1). This latter event facilitates
adhesionofmonocytestothevascularendothelium,rolling,anddia-
pedesis in the sub-endothelium with subsequent formation of foam
cells(Figure1).SecretionofIL-1andTNF-afromactivemacrophages
maintains up-regulation of adhesion molecules by enhancing NF-kB
signalling in the endothelium and also promotes smooth muscle
cells growth and proliferation
10 (Figure 1). Consistently, inhibition
ofPKCb2isoformbluntsVCAM-1up-regulationinhumanendothe-
lial cells upon glucose exposure.
27
Endothelial dysfunction in diabetes is not only the result
of impaired NO availability but also of increased synthesis of vaso-
contrictors and prostanoids.
10 PKC-mediated cyclooxygenase-2
(COX-2) up-regulation is associated with an increase of thromb-
oxane A2 and a reduction of prostacyclin (PGI2) release
28
(Figure 1). These ﬁndings suggest that PKC is the upstream signalling
molecule affecting vascular homeostasis in the setting of hypergly-
cemia
28 (Figure 1). Mitochondrial ROS also increase intracellular
levels of the glucose metabolite methylglyoxal and AGEs synthe-
sis.
12,29,30 In experimental diabetes, methylglyoxal is a key player in
the pathophysiology of diabetic complications through oxidative
stress, AGEs accumulation, and endothelial dysfunction.
29,31 Gener-
ation of AGEs leads to cellular dysfunction by eliciting activation of
the AGEs receptor (RAGE).
30,32 AGE-RAGE signalling in turn acti-
vates ROS-sensitive biochemical pathways such as the hexosamine
ﬂux.
13 In the hyperglycemic environment, an increased ﬂux of
fructose-6-phosphate activates a cascade of events resulting in dif-
ferent glycosilation patterns which are responsible for deregulation
of enzymes involved in vascular homeostasis. Speciﬁcally, O-
GlcNAcylation at the Akt site of eNOS protein leads to reduced
eNOSactivityandendothelialdysfunction.
13,33Moreover,glycosyla-
tion of transcription factors causes up-regulation of inﬂammatory
(TGFa, TGFb1) and pro-thrombotic genes (plasminogen activator
inhibitor-1).
33,34 Glucose induced-ROS production also activates
the polyol pathway ﬂux involved in vascular redox stress.
12,35 Ac-
cordingly, hyperactivation of this pathway has been associated with
increased atherosclerotic lesions in diabetic mice.
36
Insulin resistance
and atherothrombosis
Insulinresistanceisamajorfeatureoftype2diabetesanddevelopsin
multiple organs, including skeletal muscle, liver, adipose tissue, and
heart.
37 The onset of hyperglycemia and diabetes is often preceded
by many years of insulin resistance. Obesity plays a pivotal role in
this phenomenon providing an important link between type 2 dia-
betesandfataccumulation.
38Indeed,asubstantialproportionofdia-
betic patients are obese.
39 Obesity is a complex disorder leading to
alterationsinlipidmetabolism,deregulationofhormonalaxes,oxida-
tive stress, systemic inﬂammation, and ectopic fat distribution.
Adipose tissue is an active source of inﬂammatory mediators and
freefattyacids(FFAs).
40Accordingly,obesepatientswithtype2dia-
betesdisplayincreasedplasmalevelsofinﬂammatorymarkers.
41Free
fatty acids bind Toll-like receptor (TLR) activating NF-kB through
degradation of the inhibitory complex IkBa by IKKb-kinase.
42 As a
result,NF-kBtriggerstissueinﬂammationduetoup-regulationofin-
ﬂammatory genes IL-6 and TNF-a.
Toll-like receptor activation by FFA leads to phosphorylation of
insulin receptor substrate-1 (IRS-1) by c-Jun amino-terminal kinase
(JNK) and PKC, thereby altering its ability to activate downstream
targets PI3-kinase and Akt. These molecular events result in the
down-regulation of the glucose transporter GLUT-4 and, hence,
insulin resistance
43 (Figure 2). Insulin resistance is critically involved
in vascular dysfunction in subjects with type 2 diabetes.
42 Indeed,
down-regulationofPI3-kinase/AktpathwayleadstoeNOSinhibition
and decreased NO production.
44 Together with reduced NO syn-
thesis, intracellular oxidation of stored FFA generates ROS leading
tovascularinﬂammation,AGEssynthesis,reducedPGI2synthaseac-
tivity, and PKC activation
13,44 (Figure 2).
Increased ROS levels associated with insulin resistance scavenge
NOproductionandproduceperoxynitrite,withafurtherreduction
of NO bioavailability. Reduced cellular levels of NO facilitate
pro-inﬂammatorypathwaystriggeredbyincreasedcytokineproduc-
tion.Indeed,TNF-aandIL-1increaseNF-kBactivityandexpression
of adhesion molecules. TNF-a also stimulates the expression of C-
reactiveproteinwhichdown-regulateseNOSandincreasesthepro-
ductionofadhesionmoleculesandendothelin-1.
26,42Arecentstudy
clearly demonstrated that loss of insulin signalling in the vascular
endothelium leads to endothelial dysfunction, expression of adhe-
sion molecules, and atherosclerotic lesions in mice.
45
Although insulin resistance development has been attributed to
adipocyte-derived inﬂammation, recent evidence is overturning the
adipocentricparadigm.
43Indeed,inﬂammationandmacrophageacti-
vation seem to primarily occur in non-adipose tissue in obesity.
46,47
This concept is supported by the notion that suppression of inﬂam-
mation in the vasculature prevents insulin resistance in other
organs and prolongs lifespan.
48 Consistently, transgenic mice with
endothelium-speciﬁc overexpression of the inhibitory NF-kB
subunitIkBawereprotectedfromthedevelopmentofinsulinresist-
ance. In these mice, obesity-induced macrophage inﬁltration of
adipose tissue and plasma oxidative stress markers were reduced
whereas blood ﬂow, muscle mitochondrial content, and locomotor
activity were increased, conﬁrming the pivotal role of the transcrip-
tionfactorNFkBinoxidativestress,vasculardysfunction,andinﬂam-
F. Paneni et al. 2438Figure 2 Insulin resistance as trigger of atherothrombosis. In subjects with obesity or type 2 diabetes the increase in FFA activates TLR leading
NF-kB nuclear translocation and subsequent up-regulation of inﬂammatory genes IL-6 and TNF-a. On the other hand, JNK and protein kinase C
phosphorylate insulin receptor substrate-1 (IRS-1), thus blunting its downstream targets PI3-kinase and Akt. This results in down-regulation of
glucosetransporterGLUT-4and,hence,insulinresistance.ImpairedinsulinsensitivityinthevascularendotheliumleadstoincreasedFFAoxidation,
ROSformation,andsubsequentactivationofdetrimentalbiochemicalpathwayssuchasAGEsynthesis,PKCactivation,proteinglicosylationaswell
asdown-regulationofPGI2.TheseeventsblunteNOSactivitytherebyleadingtoendothelialdysfunction.Lackofinsulinsignallinginplateletsimpairs
the IRS1/PI3K pathway resulting in Ca
2+ accumulation and increased platelet aggregation. FFA, free fatty acids; TLR, toll-like receptor; JNK, c-Jun
amino-terminal kinase; IRS-1, Insulin receptor substrate-1; NO, nitric oxide; eNOS, endothelial nitric oxide shyntase; IL-6, interleukin-6; TNF-a,
tumor necrosis factor.
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48 Another study conﬁrmed these ﬁndings, showing that
geneticdisruptionoftheinsulinreceptorsubstrate2(IRS-2)inendo-
thelialcellsreducesglucoseuptakebyskeletalmuscle.
49Thesenovel
ﬁndings strengthen the central role of endothelium in obesity-
induced insulin resistance, suggesting that blockade of vascular in-
ﬂammation and oxidative stress may be a promising approach to
prevent metabolic disorders. Notably, pharmacological improve-
ment in insulin sensitivity in patients with type 2 diabetes and meta-
bolic syndrome is associated with restoration of ﬂow-mediated
vasodilation.
50–52
The atherogenic effects of insulin resistance are also due to
changes in lipid proﬁle such as high triglycerides, low HDL choles-
terol, increased remnant lipoproteins, elevated apolipoprotein B
(ApoB) as well as small and dense LDL.
53 Once circulating FFA
reach the liver, very low density lipoprotein (VLDL) are assembled
and made soluble by increased synthesis of ApoB. VLDL are pro-
cessedbycholesterylestertransferproteinallowingtransferoftrigly-
cerides to LDL, which become small and dense and, hence, more
atherogenic. Atherogenic dyslipidemia is a reliable predictor of car-
diovascularriskanditspharmacologicalmodulationreducesvascular
eventsinsubjectswithtype2diabetesandmetabolicsyndrome.
54–56
Coronaryeventsinpatientswithinsulinresistancearetriggeredby
virtue of a prothrombotic state. Under physiological conditions,
insulin inhibits platelet aggregation and thrombosis via tissue factor
(TF) inhibition and enhanced ﬁbrinolytic action due to modulation
of plasminogen activator inhibitor-1 (PAI-1) levels. Indeed, patients
with acute myocardial infarction receiving ﬁbrinolityic therapy plus
48 h insulin infusion displayed a marked decrease in PAI-1 levels.
57
In contrast, insulin resistance facilitates atherothrombosis through
increasedcellularsynthesisofPAI-1andﬁbrinogenandreducedpro-
duction of tissue plasminogen activator. In platelets, lack of insulin
leads to a down-regulation of the IRS-1/Akt pathway resulting in
calcium accumulation upon basal conditions
58 (Figure 2). This latter
mechanism may explain why platelets from diabetic patients show
faster response and increased aggregation compared with those
from healthy subjects.
59 Moreover, platelet reactivity and excretion
of tromboxane metabolites are increased in obese patients with
insulin resistance and this phenomenon is reversed by weight loss
or 3-week treatment with pioglitazone.
60 Body weight as well as
impaired insulin sensitivity may also account for the faster recovery
of cyclooxygenase activity despite aspirin treatment.
61 Indeed,
higherbodymassindexwasanindependentpredictorofinadequate
suppression of tromboxane biosynthesis in non-diabetics subjects
treated with aspirin.
61 In this study, the increase of aspirin dosage
wassufﬁcient towarrant plateletinhibition. This clinical observation
mayexplaintheresidualcardiovascularriskinobesepatientstreated
with anti-platelet medications.
Hyperglycemia and insulin resistance alone may not explain the
persistentcardiovascularriskburdenassociatedwithtype2diabetes.
Indeed, normalization of glycemia does not reduce macrovascular
events suggesting that mediators of vascular risk other than glucose
signiﬁcantly participate to increase the residual cardiovascular risk
in diabetic patients.
62 In this regard, adipose tissue dysfunction, in-
ﬂammation,andaberrantadipokinereleasemaybeparticularlyrele-
vant.
63 In patients with abdominal obesity, an increased lipid storage
leads to hypoxia, chronic inﬂammation together with changes in the
cellularcomponentsofadiposetissue,leadingtoanalteredsecretory
proﬁle. Adipokines linked to vascular disease are leptin, adipocyte
fattyacid-bindingprotein,interleukins,andnoveloneslikelipocalin-2
and pigment epithelium-derived factor. These molecules may drive
vascular dysfunction via increased proliferation/migration of
smoothmusclecells,eNOSinhibition,andactivationofNFkBsignal-
ling with subsequent expression of adhesion molecules and athero-
sclerosis.
64 Future work will need to address the potential role of
these molecules as biomarkers and/or drug targets.
MicroRNA and diabetic
vascular disease
MicroRNAs (miRs) are a newly identiﬁed class of small non-coding
RNAs emerging as key players in the pathogenesis of hypergly-
cemia-induced vascular damage.
65,66 These small non-coding RNAs
orchestrate different aspects of diabetic vascular disease by regulat-
ing gene expression at the post-transcriptional level. Microarray
studies have shown an altered proﬁle of miRs expression in subjects
with type 2 diabetes.
67–69 Indeed, diabetic patients display a signiﬁ-
cant deregulation of miRs involved in angiogenesis, vascular repair,
and endothelial homeostasis.
67 Over the last few years, different
studies have explored the mechanisms whereby deregulation of
miRs expression may contribute to vascular disease in subjects
with diabetes. In endothelial cells exposed to high glucose miR-320
is highly expressed and targets several angiogenic factors and their
receptors, including vascular endothelial growth factor and insulin-
likegrowthfactor-1(IGF-1).ElevatedlevelsofthismiRareassociated
with decreased cell proliferation and migration, while its down-
regulationrestoresthesepropertiesandincreasesIGF-1expression,
promoting angiogenesis and vascular repair
70 (Figure 3).
HyperglycemiaalsoincreasestheexpressionofmiR-221,aregula-
tor of angiogenesis targeting c-kit receptor which is responsible for
migration and homing of endothelial progenitor cells (EPCs).
71
miR-221 and222 werealsofound to mediate AGE-inducedvascular
damage.
72Indeed,down-regulationofmiR-222bothinhumanendo-
thelial cells exposed to high glucose and in diabetic mice elicits
AGE-related endothelial dysfunction via targeting, cyclin-dependent
kinase proteins involved in cell cycle inhibition (P27KIP1 and
P57KIP2).
72 A recent study demonstrated that miR-503 is critically
involvedinhyperglycemia-inducedendothelialdysfunctionindiabet-
icmiceandisup-regulatedinischaemiclimbmusclesofdiabeticsub-
jects.
73 The detrimental effects of miR-503 in the setting of diabetes
have been explained by its interaction with CCNE and cdc25A, crit-
ical regulators of cell cycle progression affecting endothelial cell mi-
gration and proliferation. Interestingly, miR-503 inhibition was able
to normalize post-ischaemic neovascularization and blood ﬂow re-
covery in diabetic mice. These ﬁndings provide the rationale to
foreseeaprotectiveeffectofthemodulation ofmiR-503expression
against diabetic vascular complications.
Plasma miR proﬁling showed a profound down-regulation of
miR-126 in a cohort of diabetic patients.
67 Recent evidence suggest
that reduced miR-126 expression levels are partially responsible
for impaired vascular repair capacities in diabetes.
74,75 miR-126 ex-
pression was reduced in EPCs isolated from diabetics and transfec-
tion with anti-miR-126 blunted EPCs proliferation and
migration.
74,75Incontrast,restoredexpressionofthismiRpromoted
F. Paneni et al. 2440EPCs-relatedrepaircapacitiesand inhibitedapoptosis.miR-126role
inEPCs function is mediated by Spred-1, an inhibitorof Ras/ERK sig-
nalling pathway, a critical regulator of cell cycle.
Collectively, these studies support the notion that miRs drive
complex signalling networks by targeting the expression of genes
involved in cell differentiation, migration, and survival.
Thrombosis and coagulation
Individuals affected by diabetes display an increased risk of coronary
events and cardiovascular mortality when compared with non-
diabetic subjects.
76–78 This phenomenon is largely explained by a
deregulation of factors involved in coagulation and platelet activa-
tion.
79,80 Both insulin resistance and hyperglycemia participate to
the pathogenesis of this prothrombotic state.
81 Insulin resistance
increases PAI-1 and ﬁbrinogen and reduces tissue plasminogen
activator levels. The largest increase in PAI-1 has been reported
in diabetic patients with poor glycemic control and treatment
with glucose-lowering agents glipizide or metformin comparably
decreased PAI-1.
82 Hyperinsulinemia induces TF expression in
monocytes of patients with type 2 diabetes leading to increased TF
procoagulant activity and thrombin generation.
83 These events are
enhanced by hyperglycemia
83,84 (Figure 4). Low-grade inﬂammation
induces TF expression also in the vascular endothelium of diabetic
subjects contributing to atherothrombosis.
81,83
Microparticles (MPs), vescicles released in the circulation from
various cell types following activation or apoptosis, are increased in
diabeticpatientsandpredictcardiovascularoutcome.
85,86Micropar-
ticles from patients with type 2 diabetes have shown to increase co-
agulation activity in endothelial cells
85 (Figure 4). Moreover, MPs
carryingTFpromotethrombusformationatsitesofinjuryrepresent-
inganovelandadditionalmechanismsofcoronarythrombosisindia-
betes.
85
Among the factors contributing to the diabetic prothrombotic
state, platelet hyperreactivity is of major relevance.
87 A number of
mechanismscontributetoplateletdysfunctionaffectingadhesion,ac-
tivation as well as aggregation phases of platelet-mediated throm-
bosis (Figure 4). Hyperglycemia alters platelet Ca
2+ homeostasis
leading to cytoskeleton abnormalities and increased secretion of
proaggregant factors.
58 Moreover, up-regulation of glycoproteins
Ib and IIb/IIIa in diabetic patients triggers thrombus via interacting
with Von Willebrand factor (vWF) and ﬁbrin molecules (Figure 4).
Figure 3 MicroRNAs involved in diabetic vascular disease. Schematic representation of microRNAs and their relative targets contributing to
reduced vascular repair and, hence, diabetes-related vascular dysfunction. VEGF, vascular endothelial growth factor; IGF-1, insulin-like growth
factor-1; ECs, endothelial cells; AGEs, advanced glycation end-products.
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Recent prospective clinical trials have shown that normalization of
glycemia failed to reduce cardiovascular burden in the diabetic
population.
88–91 In these trials, intensive glucose-lowering therapy
was started after a median duration of diabetes ranging from 8 to
11 years.
88–91 In contrast, early treatment of hyperglycemia was
shown to be beneﬁcial.
92,93 These ﬁndings support the concept
that hyperglycemic environment may be remembered in the
vasculature. Reactive oxygen species are probably involved in this
phenomenon.
94,95
The persistence of hyperglycemic stress despite blood glucose
normalization has recently been deﬁned ‘hyperglycemic memory’.
A substantial understanding of its mechanisms has been achieved
onlyinrecentyears.
96,97Ithasbeenrecentlydemonstratedthattran-
sient hyperglycemia activates NF-kB, and this effect persists despite
subsequent normalization of glucose levels. This ﬁnding is explained
by epigenetic changes occurring at the level of DNA and histone-
binding promoter of pro-oxidant and pro-inﬂammatory genes.
Speciﬁcally, methylation and acetylation are critical epigenetic
mark modulated by the hyperglycemic environment. Methylation
of p65/NFkB promoter by the ROS-dependent methyltransferase
Set7/9 is indeed the mechanisms whereby vascular inﬂammation is
not reverted by restoration of normoglycemia
98 (Figure 5). We
haverecentlyidentiﬁedthesourceofROSperpetuatingvasculardys-
function despite normoglycemia restoration.
18
In diabetic mice and human endothelial cells, glucose normaliza-
tion did not revert up-regulation of p66
Shc protein, a mitochondrial
adaptor critically involved in ROS generation.
18 Persistent p66
Shc
expression is driven by epigenetic changes as reduced promoter
methylation and acetylation of histone 3 (Figure 5). Moreover,
p66
Shc-dependent ROS generation maintains up-regulation of
PKCbII and inhibits eNOS activity, thus feeding a detrimental
vicious cycle despite restoration of normoglycemia
18 (Figure 5). Per-
sistent oxidative stress is also responsible for sustained vascular
apoptosis via caspase 3 activation. Gene silencing of p66
Shc blunted
persistent endothelial dysfunction and oxidative stress in the vascu-
lature of diabetic mice, suggesting that this protein drives hypergly-
cemic memory
18 (Figure 5). In addition, other studies have shown
that both mammalian deacetylase SIRT-1 and tumour suppressor
p53haveastrongmemoryeffectdespiteglucosenormalization.
99,100
Interestinglyenough,theseﬁndingsareinlinewiththenotionthat
both SIRT-1 and p53 control p66
Shc transcription.
101,102 Indeed,
reduced SIRT-1 activity in diabetes favours acetylation of histone
3-binding p66
Shc promoter. Moreover, increased p53 activity main-
tainsp66
Shcmemoryeffect (Figure5).
101,102Alltogether,thesepath-
ways might be involved in self-perpetuating vascular damage of
patients with diabetes despite optimal glycemic control.
Figure 4 Coagulation and platelet reactivity in diabetes. In patients with diabetes chronic hyperglycemia and insulin resistance determine a sig-
niﬁcant alteration in the coagulation factors as well as increased platelet aggregation, leading to a prothrombotic state. Diabetes-induced increase
of TF levels activatesthrombin converting ﬁbrinogen into ﬁbrin. Fibrin organization is further enhanced due to high PAI-1 and reducedt-PA levels.
IncreasedCa
2+ content, thrombinstimulation as wellas interaction with vWF via gpIIb/IIIa receptor lead to plateletshape change, granulerelease,
and aggregation. Release of MPs from injured endothelium and circulating platelets contribute to accelerate thrombus development. Endothelial
dysfunctionprecipitatesruptureoftheendotheliallayerleadingtoexposureofcollagenandvWFtherebyactivatingplateletsandfavouringvascular
thrombosis.TF,tissuefactor;t-PA,tissueplasminogenactivator;PAI-1,plasminogenactivatorinhibitor-1;MPs,microparticles;vWF,vonWillebrand
factor; ECs, endothelial cells.
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Oxidativestressplaysamajorroleinthedevelopmentofmicro-and
macrovascular complications. Accumulation of free radicals in the
vasculature of diabetic patients is responsible for the activation of
detrimental biochemical pathways, miRs deregulation, release of
MPs, and epigenetic changes contributing to vascular inﬂammation
and ROS generation. Since cardiovascular risk burden is not eradi-
catedbyintensiveglycemiccontrolassociatedwithoptimalmultifac-
torial treatment, mechanism-based therapeutic strategies are in
highly demand.
88–91 Speciﬁcally, inhibition of key enzymes involved
inhyperglycemia-inducedvasculardamageoractivationofpathways
improving insulin sensitivity may represent promising approaches.
Modulation of speciﬁc miRs might contribute to improve EPC-
driven vascular repair. Moreover, the progressive identiﬁcation of a
complex scenario driven by epigenetic changes that modulate tran-
scriptionofROS-generatingandpro-inﬂammatorygenesmayrepre-
sent an attractive opportunity to dampen oxidative stress, vascular
inﬂammation, and hence to prevent cardiovascular complications in
patients with diabetes.
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